Vertex Finally Inks Orkambi Deal In England
Stalemate Over As Parties Agree Deal That Also Includes Symkevi And Kalydeco
Vertex has finally managed to reach an agreement to bring its cystic fibrosis drugs Orkambi and Symkevi to patients in England, which constitutes an important slice of what is the second biggest market for the drugs.
You may also be interested in...
Three BRICS Launch Generic Challenge For Vertex’s Landmark CF Therapy
With a suite of vastly expensive and advanced cystic fibrosis therapies entirely under its command, Vertex is facing more heat from patients and advocates in several major low- and middle-income countries.
US Pharma Firms Not In Post-Brexit Trade Talks
A UK TV program revealed secret meetings between drug makers and British civil servants but for its part, the American Pharmaceutical Group says it has had no discussions
Vertex Versus NHS England: Was The Stand-Off Worth It?
After three years as the pharma bogeyman, Vertex has agreed a deal in England. So what purpose did the stand-off serve?